Table 2.

Characteristics of cases reported with pregnancy outcomes after IFN-α exposure in patients with viral hepatitis.

Reference	Year	Country	Age	Type of IFN	Disease	Exposed period	Outcome	Exposed details
Hiratsuka, et al. (36)	2000	Japan	44	IFN-α	HCV	13th week to 33rd week of gestation	healthy male infant	5 MU, 2–4 times a week, a total dose of 315MU
Suda, et al. (37)	1999	Japan	21	IFN-α	HCV	Third trimester of pregnancy (half of year)	healthy female infant	2.5MU, 3 times per week for half a year
Atasoy, et al. (38)	2017	Turkey	39,28	PEG IFNα-2b	HBV	first trimester	healthy infant	10th week to16th week of gestation
Özaslan, et al. (39)	2002	Turkey	26	IFN-α	HCV	from 16th week of gestation	healthy infant	3 MU, 3 times per week for 2.5 months
Makin, et al. (40)	2013	Japan	25	IFN-α	HBV	during the second trimester	healthy female infant	3MU, 2 weeks during the second trimester
Ruggiero, et al. (41)	1996	Italy	42	IFN-α	HCV	the first 5 months of gestation	healthy female infant	3 MU, 3 times per week
Trotter, et al. (42)	2001	United States	27	IFN-α	HCV	first trimester	healthy female infant	3 MU, 3 times per week
Daniel, et al. (43)	2001	Canada	29	IFN-α-2b	HCV	became pregnant 3.5 months after discontinuing treatment	healthy female infant	3 MU, 3 times per week